Study of Adherence Effects and Clinical Outcomes of Kaletra Based HIV Antiviral Therapy

Stopped early · Phase 4

Conditions studied: HIV Infection

In brief

The purpose of this study is to evaluate the effects of adherence on HIV antiviral response to treatment regimens containing Kaletra or other HIV protease inhibitors.

Key facts

Study ID

NCT00234962

Run by

Abbott

People needed

200

Starts

2002-08-01

Expected to finish

2007-02-01

Last updated by the study team

2008-11-21

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subject is documented HIV positive
• Subject is greater than or equal to 18 years of age.
• Subject currently on a regimen of either NNRTI + 2 Nucleoside Reverse Transcriptase Inhibitors NRTIs), two or three NRTIs who have failed regimen as evidenced by two consecutive viral loads with values over 1,000 copies/mL, the last one within the last three months, or
• Naïve subjects to ARV regimen who are required to begin a PI containing HAART regimen, or
• Subjects who have become intolerant to their current antiretroviral regimen and are required to be changed to a first time PI containing HAART regimen.
• Subject had laboratory testing within the previous three months and the most recent testing demonstrates all of the following: Hemoglobin >8.0 g/dL; Absolute neutrophil count >750 cells/mL; Platelet count >20,000/mL; ALT or AST <3 x Upper Limit of Normal (ULN); Creatinine <1.5 x ULN; Triglycerides <750 mg/dL.
• Subjects have no have evidence of grade III or IV adverse event or laboratory abnormality.

Where it is running

• Global Medical Information - Abbott — North Chicago, Illinois, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.